First-of-its-Kind combo targets untreatable blood cancer
NCT ID NCT05943496
Summary
This early-stage trial is testing the safety and initial effectiveness of a new three-drug combination for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The treatment combines two antibody drugs (tafasitamab and obinutuzumab) with a pill (acalabrutinib) to attack cancer cells in different ways. The main goals are to see if the combination is safe and if it can reduce cancer to undetectable levels in the blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.